Global Tumor Embolization Devices Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends
25 Oct, 2021
The tumor embolization devices market consists of sales of tumor embolization devices and related services by entities (organizations, sole traders and partnerships) that manufacture tumor embolization devices. Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. Only goods and services traded between entities or sold to end consumers are included.
Global Tumor Embolization Devices Market Size And Drivers:
The global tumor embolization devices market is expected to grow from $1.36 billion in 2020 to $1.51 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.16 billion in 2025 at a CAGR of 9%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the tumor embolization devices market during the forecast period.
Request For A Sample For The Global Tumor Embolization Devices Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp
Trends In The Global Tumor Embolization Devices Market
Companies in the tumor embolization devices market are increasingly investing in technological advances to provide more efficient devices to the consumers. The advances include the emergence of biocompatible, biodegradable, drug-eluting microspheres that provide effective embolization. Bioresorbable microspheres block the blood vessels causing tumors without long-term blockage of the healthy tissue blood vessels. In 2019, QXMédical announced its decision to license bioresorbable embolic technology from the University of Minnesota, to be used in tumor embolization devices for cancer and tumor treatment.
Global Tumor Embolization Devices Market Segments:
The global tumor embolization devices market is further segmented –
By Type: Radioembolic Agents, Non-radioactive Embolic Agents
By Application: Cancer Tumors, Noncancerous Tumors
By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers
By Geography: The global tumor embolization devices market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Report For The Global Tumor Embolization Devices Market At:
https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report-2020-30-covid-19-growth-and-changeTumor Embolization Devices Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides tumor embolization devices market overviews, analyzes and forecasts market size and growth for the global tumor embolization devices market, tumor embolization devices market share, tumor embolization devices market players, tumor embolization devices market segments and geographies, tumor embolization devices market’s leading competitors’ revenues, profiles and market shares. The tumor embolization devices market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.